Nektar Therapeutics (NKTR) Misses Q1 EPS by 4c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $71.04 +10.33%
Revenue Growth %: -7.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CRMT, More
Revenue Growth %: -7.1%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $14.49 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Goldman's Garrett sees investors dialing back tech exposure into H2
- SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
